LONG-TERM OUTCOME OF STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH ACOUSTIC NEUROMAS
|
|
- Lenard McLaughlin
- 5 years ago
- Views:
Transcription
1 doi: /j.ijrobp Int. J. Radiation Oncology Biol. Phys., Vol. 64, No. 5, pp , 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved /06/$ see front matter CLINICAL INVESTIGATION Brain LONG-TERM OUTCOME OF STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH ACOUSTIC NEUROMAS STEPHANIE E. COMBS, M.D.,* CHRISTOPH THILMANN, M.D.,* JÜRGEN DEBUS, M.D., PH.D.,* AND DANIELA SCHULZ-ERTNER, M.D.* *Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany; and Department of Radiation Oncology, German Cancer Research Center, Heidelberg, Germany Purpose: To evaluate the effectiveness and long-term outcome of stereotactic radiosurgery (SRS) for acoustic neuromas (AN). Patients and Methods: Between 1990 and 2001, we treated 26 patients with 27 AN with SRS. Two patients suffered from neurofibromatosis type 2. Before SRS, a subtotal or total resection had been performed in 3 and in 5 patients, respectively. For SRS, a median single dose of 13 Gy/80% isodose was applied. Results: The overall actuarial 5-year and 10-year tumor control probability in all patients was 91%. Two patients developed tumor progression after SRS at 36 and 48 months. Nineteen patients (73%) were at risk of treatmentrelated facial nerve toxicity; of these, 1 patient developed a complete facial nerve palsy after SRS (5%). A total of 93% of the lesions treated were at risk of radiation-induced trigeminal neuralgia. Two patients (8%) developed mild dysesthesia of the trigeminal nerve after SRS. The hearing preservation rate in patients with useful hearing before SRS was 55% at 9 years. Conclusion: Stereotactic radiosurgery results in good local control rates of AN and the risk of cranial nerve toxicities is acceptable. As toxicity is lower with fractionated stereotactic radiotherapy, SRS should be reserved for smaller lesions Elsevier Inc. Vestibular schwannoma, Stereotactic radiosurgery, Hearing preservation, Local control. INTRODUCTION Reprint requests to: Stephanie E. Combs, MD, Department of Radiation Oncology, University of Heidelberg, Im Neuenheimer Feld 400, Heidelberg, Germany. Tel: ( 49) ; Fax: ( 49) Acoustic neuromas (AN) occur with an incidence of 1 per 100,000 of the population and are benign tumors commonly arising from the vestibular branch of the eighth cranial nerve (1). They present as extracanalicular tumors, intracanalicular tumors, or within the cerebellopontine angle. Generally, one can observe a very slow growth pattern with an increase in diameter of no more than 1 mm per year (1). In recent years, several treatment options for patients with AN have been established. Microsurgery is considered the standard approach, offering both immediacy of tumor removal and low rates of recurrences (2 5). However, surgery might be associated with a marked incidence of cranial and noncranial nerve morbidities, although modern microsurgical techniques have significantly decreased morbidity and mortality (3, 6 9). Conventional radiation therapy has been employed to prevent local tumor progression in cases of recurrent of residual tumors (10). Modern radiotherapeutic treatment options such as fractionated stereotactic radiotherapy (FSRT) offer a noninvasive treatment with tumor control rates comparable to microsurgery, but with a higher rate of hearing preservation and preservation of facial and trigeminal nerve function (11 13). Stereotactic radiosurgery (SRS) has been shown to be another noninvasive treatment alternative to microsurgical resection or FSRT in patients with smaller AN (1, 14, 15). It can be performed as gamma knife radiosurgery or as linac-based radiosurgery. Leksell and Norén were the first to report very favorable outcomes in patients treated with gamma knife radiosurgery in the 1960s (16, 17). The technique of SRS aims at focusing multiple beams of radiation on a defined target (17). With the subsequent introduction of linear accelerators (linac) dedicated to stereotactic treatments, linac-based SRS has become a cost-effective alternative to gamma knife radiosurgery. For both radiosurgical treatment options, complications include hearing loss, facial weakness and numbness, tinnitus, imbalance, headache, dysarthria, dysphagia, cystic necrosis, and hydrocephalus (18). Results obtained with SRS in the treatment of AN are comparable with those achieved with gamma knife radiosurgery with respect to local control and complications (13, 19 22). The main advantage of SRS as compared with FSRT is the application of the therapeutic dose in a ; Stephanie.Combs@med.uni-heidelberg.de Received Oct 7, 2005, and in revised form Oct 27, Accepted for publication Oct 31,
2 1342 I. J. Radiation Oncology Biology Physics Volume 64, Number 5, 2006 single fraction, minimizing treatment times and potential hospitalization times. Especially older patients or patients with a number of comorbidities are likely to benefit from the reduced treatment time. The present analysis reports on our results obtained in 26 patients with AN treated with SRS in our institution with special respect to long-term treatment outcome including local tumor control and radiation-induced side effects. PATIENTS AND METHODS Between 1990 and 2000, we treated 26 patients with SRS for 27 AN at a single institution. All patients were followed prospectively and no patient was lost to follow-up. Eighteen patients were female and 8 patients were male. The median age at SRS was 64 years (range, years). The median age at primary diagnosis of the AN was 64 years (range, years), with a median time between diagnosis and SRS of 5 months (range, 1 72 months). The AN was localized on the right vestibular nerve in 13 patients, on the left vestibular nerve in 11 patients, and bilaterally in 2 patients. Two patients suffered from neurofibromatosis type 2, and of these 2 patients, 1 patient presented with bilateral AN. In patients with bilateral AN, only the side treated with SRS was included into this analysis. Twenty-one tumors were localized intra- and extracanalicularly, and two and four tumors were localized intracanalicularly or extrancanaliculary only. The median tumor diameter was 15 mm (range, 2 28 mm). The tumor size distribution according to the largest diameter can be found in Fig. 1a. Before SRS, in 3 patients a subtotal resection and in 5 patients a total resection of the AN had been performed. In these cases SRS was performed as salvage therapy for recurrent or progressive tumors. In 1 patient, a neurosurgical resection of a contralateral AN had been performed. All patients were treated using a single, high-dose radiation treatment as described previously (23). For treatment planning and for subsequent SRS, an individual precision head mask system made of Scotch cast was manufactured for each patient (24, 25). This fixation system allows a positioning accuracy of 1 2 mm. With the mask system attached to a stereotactic localization system attached to the base frame, contrast-enhanced computed tomography and magnetic resonance imaging scans were acquired with a slice thickness of 3 mm (26, 27). After stereotactic image fusion, the target volume and organs at risk were defined on each slice of the three-dimensional data cube using the three-dimensional treatment planning system STP (Stryker-Leibinger, Freiburg, Germany) or the VIRTUOS planning program (dkfz, Heidelberg, Germany). The planning target volume was defined as the area of contrast enhancement on T1-weighted magnetic resonance imaging including a 1 2 mm safety margin for possible patient misalignment. Radiosurgery was delivered with circular collimators or, for irregularly shaped AN, with a multileaf collimator (leaf width, 1.5 mm at isocenter). The prescribed dose was chosen after evaluation of the dose volume histogram with respect to the size of the planning target volume, hearing evaluation, and the localization of the AN. A median single dose of 13 Gy (range, Gy) was prescribed to the 80% isodose (Fig. 1b). All patients received 20 mg dexamethasone 1 h before and 6 h after radiosurgery, together with H 2 -antihistamine for stomach ulcer prophylaxis. All patients were seen 6 weeks after SRS for a first follow-up visit, and thereafter in 3- to 6-months intervals for the first 2 3 years. Thereafter, yearly follow-up examinations were performed. All follow-up visits included a thorough neurologic assessment and a contrast-enhanced magnetic resonance imaging scan. Hearing evaluation was recommended to be performed by the patients home otolaryngologist on a regular basis and was available to evaluate hearing function. For the evaluation of SRS-related side effects and the long-term outcome, a detailed questionnaire was sent out to all patients. Pre- and posttreatment hearing was classified according to the Gardner-Robertson modification of the classification system of Silverstein (28). For hearing classification, we included information from the patients charts, hearing evaluations performed before and after radiotherapy by the patients otolaryngologists, or data collected from the primary care physicians and the patient questionnaire. Useful hearing in the treated ear was considered if patients qualified as Gardner Robertson Class I or II. Local control and hearing preservation probability were calculated using the Kaplan-Meier method. For intergroup differences, the log rank test was applied. All statistical analyses were performed using Statistica 6.0 (StatSoft, Hamburg, Germany). RESULTS Local tumor control The overall actuarial 5- and 10-year tumor control probability in all patients was 91% (Fig. 2). In the group consisting of patients with sporadic AN, local control was 96% (a) 3cm 11% (b) 1cm 37% 2cm 52% Fig. 1. (a) Tumor size distribution according to the largest tumor diameter. (b) Dose distribution with respect to the largest tumor diameter.
3 SRS for acoustic neuroma S. E. COMBS et al intermittently developed incomplete facial nerve palsy on the side of the AN treated with SRS (15%). Two patients presented with symptoms of typical trigeminal neuralgia before radiotherapy. One of the 2 patients had undergone a total neurosurgical resection of the AN and received SRS for tumor progression. The second patient without any prior treatment of the AN experienced pain relief during follow-up after SRS. A total of 93% of the lesions treated (25 out of 27) was at risk of developing radiation-induced trigeminal neuralgia. Two of these patients (8%) developed mild dysesthesia of the trigeminal nerve after SRS, 1 of whom had also developed necrosis of the AN and within the cerebellum after SRS. Fig. 2. Local control after stereotactic radiosurgery. at 5 and 91% at 10 years, respectively. In patients suffering from neurofibromatosis type 2 (NF-2) (n 2), local tumor control was 100% at 10 years. This difference was not significantly different at p 0.84 (log rank). We analyzed the difference in local tumor control with regard to previously performed neurosurgical intervention. For previously untreated patients, local tumor control was 94% at 5 and 10 years after SRS as compared to 88% at 5 and 10 years in the patient group that had received prior neurosurgical resection. This difference was not significant at p 0.54 (log rank). Two patients developed tumor progression after SRS at 36 and 48 months. Of these 2 patients, 1 patient had undergone neurosurgery before SRS and tumor progression. Treatment-related toxicity Stereotactic radiosurgery was well tolerated in all patients. No severe acute toxicity Common Toxicity Criteria Grade 2 occurred. The median follow-up time after SRS was 110 months (range, months). During the follow-up period, 1 patient developed a radiologically confirmed necrosis of the AN and a small necrotic lesion within the cerebellum with peripheral contrast enhancement. In another patient an intermittent disruption of the blood brain barrier developed 3 months after SRS that persisted until 41 months after SRS and disappeared thereafter. No other severe long-term toxicities Common Toxicity Criteria degree 2 could be observed. At the time point of SRS, 8 patients presented with complete or incomplete facial nerve palsy. Of these patients, 5 had received a complete neurosurgical resection before RT and received SRS for tumor progression. Three patients presented with facial nerve palsy without any prior treatment. Of all 27 lesions treated with SRS, 19 (73%) were at risk for treatment-related facial nerve toxicity. One patient of the 19 patients at risk developed a complete facial nerve palsy after SRS (5%). Three patients Hearing preservation Hearing impairment was the leading symptom for the diagnosis of AN or aggravated during a surveillance period. At the time of referral, 35% of patients presented with nonserviceable hearing, which means hearing loss or any testable hearing that was not useful. Seventeen patients out of 26 (65%) presented with useful hearing before SRS and were at risk of developing treatment-related hearing loss after radiotherapy. New hearing loss or hearing impairment considered as no longer useful after SRS was found in 5 patients. The hearing preservation rate in patients with useful hearing before SRS was 55% at 9 years after SRS (Fig. 3). Hearing preservation rates were not significantly different in patients with sporadic AN as compared with patients with NF-2 (p 0.72, log rank). Additionally, there was no statistical difference in hearing preservation with regard to tumor size ( 1 cm vs. 1 cm; p 0.4) and tumor size in combination with the prescribed dose ( 1 cm and 15 Gy vs. all other patients; p 0.4, log rank). Previously performed neurosurgical resection did not influence the hearing preservation rate in patients presenting with useful hearing (p 0.4, log rank). In patients with nonuseful hearing before SRS, residual hearing function, which was, however, not useful, was preserved in 50% at 7 years after SRS. Fig. 3. Hearing preservation with respect to useful and nonuseful hearing before stereotactic radiosurgery.
4 1344 I. J. Radiation Oncology Biology Physics Volume 64, Number 5, 2006 DISCUSSION Over the past decades, several treatment options for patients with AN have emerged. Microsurgery, SRS, and FSRT have an established role in the treatment of AN, and physicians as well as patients are faced with the choice between these treatment alternatives. However, each procedure is associated with certain benefits for the patient as well as with a specific toxicity spectrum that has to be considered in the choice of the optimal treatment for each individual patient. Tumor size, hearing level on the affected side, and the patient s preference should be taken into account before opting for any treatment modality. In general, observation of the diagnosed AN might be indicated in a number of situations, especially in elderly and/or medically unfit patients without progressive neurologic symptoms or long-tract, brainstem, or cerebellar signs apparent on clinical presentation. Additionally, in patients with bilateral AN with perhaps only residual hearing on the affected side, or any patients with deafness on the contralateral ear, as well as patients generally refusing treatment, a wait-and-see strategy can be justified. However, microsurgery is still considered the standard approach for the treatment of AN. In principle, there are three different microsurgical approaches: the middle fossa, translabyrinthine, and the suboccipital approach. Each surgical approach is associated with a distinct risk for cranial nerve damage, including hearing loss and loss of facial and trigeminal nerve function (29 31). The middle and posterior fossa approaches are useful for hearing preservation surgery, especially in smaller tumors, but are associated with a higher risk for facial nerve palsies (9, 32 34). Hearing preservation rates of 31 59% were reported for these techniques (29, 30, 35, 36). For the suboccipital approach, hearing preservation rates from 11% to 83% were reported (34, 37 39). However, although useful for the resection of smaller or medium sized tumors, the translabyrinthine approach does not allow hearing preservation. As a noninvasive alternative to surgery, a number of radiotherapeutic techniques have evolved and have been established for the treatment of AN, providing excellent local tumor control as compared with surgery, however, with a smaller risk of therapy-related side effects to the cranial nerves. Stereotactic radiosurgery, a concept introduced by Leksell in 1951, has been shown to be a viable and effective alternative therapy for patients with AN (19, 22, 40, 41). It permits the application of a high single dose to a stereotactically defined treatment volume while enabling a steep dose falloff around the target volume, sparing normal tissue in close vicinity (4, 42). SRS can be delivered by a 60 Co gamma knife or a linac. The gamma knife was first used for AN by Leksell in 1969 (17). A main advantage of SRS is the application of an effective treatment dose in a single session, resulting in minimal treatment duration and hospitalization times. This can be extremely useful in treating elderly patients, patients with a number of comorbidities, or patients refusing to accept the necessity for weeklong therapies. Additionally, patients with claustrophobia or panic because of the fixation device can profit from this single-dose treatment, because anxiolytic medication only has to be administered for treatment planning and thereafter for the single treatment session. However, despite the numerous benefits, SRS is associated with an increased risk for loss of hearing function and for treatment-related toxicity to the facial and trigeminal nerves as compared with fractionated RT regimens. Several studies evaluating the effectiveness of SRS in the management of AN have shown that local tumor control is highly comparable to microsurgery. Karpinos et al. could show tumor control rates of 91% for SRS as compared with 100% achieved by microsurgery (18). Several other studies have reported similar control rates of % at 2 12 year follow-up for patients treated with SRS (12, 43 47). Generally, local control rates are higher for smaller tumors than for large lesions treated with SRS. Forster et al. could show that AN greater than 3 cm had a control rate of 33% and tumors measuring 2 3 cm showed a growth control of 86%. Tumors of 2 cm could be controlled in 89% (48). For microsurgery, local tumor control correlated strongly with the amount of tumor removed, with control rates of up to 100% after total resections, and of 45 95% for subtotal resections (31, 49, 50). In our study, local tumor control for patients with sporadic AN was 96% and 91% at 5 and 10 years, respectively. Tumor size in our patient group did not have a significant impact on local control after SRS. For FSRT, similar local tumor control rates of 91% to 100% have been reported (51 53). However, with respect to cranial nerve toxicity, patients are likely to profit from fractionated treatment schemes. With FSRT, treatment-related toxicity to the facial nerve of 0 3% can be found in the literature (14, 51 57). With microsurgery, the rate of cranial nerve toxicity depends strongly on the size of the AN. Small tumors are associated with 0 6% facial neuropathies; in medium-sized tumors, rates of 8 24% of facial neuropathies can be observed; and in patients with large tumors, facial palsy rates of 40% to 80% could be found (31, 58). Treatment of AN with SRS may lead to facial nerve toxicity rates of 0 23% as reported in different studies (12, 13, 16, 18, 52, 59, 60). In a study published by Karpinos et al., the rate of facial neuropathy immediately after treatment was 0% after SRS vs. 35% after microsurgery and 6.1% vs. 35.3% at long-term follow-up, respectively (18). These results were also supported by Pollack et al., who reported higher postsurgical toxicity to the facial nerve as compared with SRS. In the present study, the rate of facial nerve neuropathy after SRS was 5% for complete facial palsy after SRS. These results support previous data indicating that facial nerve toxicity is comparably low with SRS. However, by implementing a fractionated RT scheme toxicity rates can be further reduced as indicated above. With respect to trigeminal nerve function, toxicity rates of 4 27% after SRS are reported in the literature. Several
5 SRS for acoustic neuroma S. E. COMBS et al studies indicate that the risk for trigeminal neuropathy is higher after microsurgery. Karpinos et al. could show that immediate postoperative trigeminal toxicity was 17% after microsurgery as opposed to 0% after SRS, and 22% vs. 12.2% at long-term follow-up (18). In the present report, the rate of trigeminal nerve toxicity was 8%, consisting only of mild dysesthesia of the trigeminal nerve. One of the main goals in the management of AN is the preservation of hearing function after treatment. For microsurgery, hearing preservation strictly depends on the size of the tumor, the choice of the surgical approach, and, last, the experience of the surgeon (9, 29 35, 38, 61). The results of hearing preservation obtained by SRS are generally comparable with those after microsurgery. Karpinos et al. reported on serviceable hearing preservation rates of 44% and 40% for radiosurgery and microsurgery, respectively (18). Patients treated with a middle fossa and suboccipital microsurgical approach in their study presented with hearing preservation rates of 25% for small and 0% for larger tumors. Pollack et al. found a significantly higher serviceable hearing preservation rate in patients treated with radiosurgery than in patients treated with microsurgery (61). This is supported by a number of studies reporting on serviceable hearing preservation rates of 26 65% at 1 10 years follow-up (45, 49, 62 65). In the present study, hearing preservation in patients with useful or serviceable hearing before RT was 55% at 9 years after SRS. We could not find a significance in hearing preservation with regard to size of the tumors or presence of NF-2. A possible explanation is that the doses were prescribed taking into account the size of the AN, which might mask the possible effect of the RT volume on toxicity. However, although hearing preservation is comparable with or better than results obtained by microsurgery, fractionated precision RT provides a radiobiologic advantage of fractionation to further improve hearing preservation. Patients treated with FSRT at our institution showed serviceable hearing preservation rate of 94% after 5 years (57). In a study published by Meijer et al., hearing preservation after FSRT was 64% at 5 years, and Flickinger et al. found a hearing preservation rate of 78.6% 5.1% at 6 years (52, 64). In conclusion, radiosurgical treatment of AN is a feasible and effective treatment alternative to microsurgery and FSRT. It is associated with a low rate of immediate and long-term toxicity by means of facial and trigeminal neuropathy as compared with microsurgery. Hearing preservation rates and local control rates are comparable with those achieved by microsurgery. However, with FSRT, cranial nerve toxicity can be further reduced. Obvious benefits of SRS are the noninvasive approach and the application of the therapeutic dose in a single fraction. Although, as a radiotherapeutic alternative to microsurgery, FSRT is the recommended treatment of choice in our institution, SRS is reserved for patients with very small AN, and for elderly patients and patients with comorbidities certainly profiting from the reduction of hospitalization and treatment times. REFERENCES 1. Perks JR, St. George EJ, El Hamri K, et al. Stereotactic radiosurgery XVI: Isodosimetric comparison of photon stereotactic radiosurgery techniques (gamma knife vs. micromultileaf collimator linear accelerator) for acoustic neuroma and potential clinical importance. Int J Radiat Oncol Biol Phys 2003;57: Wiegand DA, Fickel V. Acoustic neuroma the patient s perspective: Subjective assessment of symptoms, diagnosis, therapy, and outcome in 541 patients. Laryngoscope 1989;99: Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): Surgical management and results with an emphasis on complications and how to avoid them. Neurosurgery 1997;40: Sluyter S, Graamans K, Tulleken CA, et al. Analysis of the results obtained in 120 patients with large acoustic neuromas surgically treated via the translabyrinthine-transtentorial approach. J Neurosurg 2001;94: Ojemann RG. Management of acoustic neuromas (vestibular schwannomas) (honored guest presentation). Clin Neurosurg 1993;40: Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): The facial nerve preservation and restitution of function. Neurosurgery 1997;40: Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): Hearing function in 1000 tumor resections. Neurosurgery 1997;40: Wiegand DA, Ojemann RG, Fickel V. Surgical treatment of acoustic neuroma (vestibular schwannoma) in the United States: Report from the Acoustic Neuroma Registry. Laryngoscope 1996;106: Glasscock ME III, Hart MJ, Vrabec JT. Management of bilateral acoustic neuroma. Otolaryngol Clin North Am 1992;25: Wallner KE, Sheline GE, Pitts LH, et al. Efficacy of irradiation for incompletely excised acoustic neurilemomas. J Neurosurg 1987;67: Foote RL, Coffey RJ, Swanson JW, et al. Stereotactic radiosurgery using the gamma knife for acoustic neuromas. Int J Radiat Oncol Biol Phys 1995;32: Kondziolka D, Lunsford LD, McLaughlin MR, et al. Longterm outcomes after radiosurgery for acoustic neuromas. N Engl J Med 1998;339: Mendenhall WM, Friedman WA, Buatti JM, et al. Preliminary results of linear accelerator radiosurgery for acoustic schwannomas. J Neurosurg 1996;85: Andrews DW, Suarez O, Goldman HW, et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: Comparative observations of 125 patients treated at one institution. Int J Radiat Oncol Biol Phys 2001;50: Fuss M, Debus J, Lohr F, et al. Conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas. Int J Radiat Oncol Biol Phys 2000;48: Noren G, Greitz D, Hirsch A, et al. Gamma knife surgery in acoustic tumours. Acta Neurochir Suppl (Wien) 1993;58: Leksell L. A note on the treatment of acoustic tumours. Acta Chir Scand 1971;137: Karpinos M, Teh BS, Zeck O, et al. Treatment of acoustic neuroma: Stereotactic radiosurgery vs. microsurgery. Int J Radiat Oncol Biol Phys 2002;54: Foote KD, Friedman WA, Buatti JM, et al. Analysis of risk
6 1346 I. J. Radiation Oncology Biology Physics Volume 64, Number 5, 2006 factors associated with radiosurgery for vestibular schwannoma. J Neurosurg 2001;95: Suh JH, Barnett GH, Sohn JW, et al. Results of linear accelerator-based stereotactic radiosurgery for recurrent and newly diagnosed acoustic neuromas. Int J Cancer 2000;90: Meijer OW, Wolbers JG, Baayen JC, et al. Fractionated stereotactic radiation therapy and single high-dose radiosurgery for acoustic neuroma: Early results of a prospective clinical study. Int J Radiat Oncol Biol Phys 2000;46: Spiegelmann R, Lidar Z, Gofman J, et al. Linear accelerator radiosurgery for vestibular schwannoma. J Neurosurg 2001; 94: Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998;16: Menke M, Hirschfeld F, Mack T, et al. Photogrammetric accuracy measurements of head holder systems used for fractionated radiotherapy. Int J Radiat Oncol Biol Phys 1994; 29: Karger CP, Hartmann GH, Heeg P, et al. A method for determining the alignment accuracy of the treatment table axis at an isocentric irradiation facility. Phys Med Biol 2001;46: N19 N Debus J, Kocagoncu KO, Hoss A, et al. Fractionated stereotactic radiotherapy (FSRT) for optic glioma. Int J Radiat Oncol Biol Phys 1999;44: Schulz-Ertner D, Frank C, Herfarth KK, et al. Fractionated stereotactic radiotherapy for craniopharyngiomas. Int J Radiat Oncol Biol Phys 2002;54: Gardner G, Robertson JH. Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol 1988; 97: Shelton C, Brackmann DE, House WF, et al. Acoustic tumor surgery. Prognostic factors in hearing conversation. Arch Otolaryngol Head Neck Surg 1989;115: Shelton C, Brackmann DE, House WF, et al. Middle fossa acoustic tumor surgery: Results in 106 cases. Laryngoscope 1989;99: Gormley WB, Sekhar LN, Wright DC, et al. Acoustic neuromas: Results of current surgical management. Neurosurgery 1997;41: Cohen NL. Retrosigmoid approach for acoustic tumor removal. Otolaryngol Clin North Am 1992;25: Maniglia AJ, Fenstermaker RA, Ratcheson RA. Preservation of hearing in the surgical removal of cerebellopontine angle tumors. Otolaryngol Clin N Am 1989;22: Nedzelski JM, Tator CH. Hearing preservation: A realistic goal in surgical removal of cerebellopontine angle tumors. J Otolaryngol 1984;13: Sanna M, Zini C, Mazzoni A, et al. Hearing preservation in acoustic neuroma surgery. Middle fossa versus suboccipital approach. Am J Otol 1987;8: Wade PJ, House W. Hearing preservation in patients with acoustic neuromas via the middle fossa approach. Otolaryngol Head Neck Surg 1984;92: Shelton C, Alavi S, Li JC, et al. Modified retrosigmoid approach: Use for selected acoustic tumor removal. Am J Otol 1995;16: Frerebeau P, Benezech J, Uziel A, et al. Hearing preservation after acoustic neurinoma operation. Neurosurgery 1987;21: Sterkers JM, Desgeorges M, Sterkers O, et al. [Surgery of acoustic neuroma and other tumors of the internal auditory canal and cerebellopontile angle. Apropos of 602 cases]. Ann Otolaryngol Chir Cervicofac 1986;103: Flickinger JC, Kondziolka D, Niranjan A, et al. Results of acoustic neuroma radiosurgery: An analysis of 5 years experience using current methods. J Neurosurg 2001;94: Flickinger JC, Kondziolka D, Lunsford LD. Clinical applications of stereotactic radiosurgery. Cancer Treat Res 1998;93: Combs SE, Schulz-Ertner D, Thilmann C, et al. Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther Onkol 2004;180: Flickinger JC, Kondziolka D, Lunsford LD. Dose and diameter relationships for facial, trigeminal, and acoustic neuropathies following acoustic neuroma radiosurgery. Radiother Oncol 1996;41: Lunsford LD, Linskey ME. Stereotactic radiosurgery in the treatment of patients with acoustic tumors. Otolaryngol Clin North Am 1992;25: Hirsch A, Noren G. Audiologic findings after stereotactic radiosurgery in acoustic neurinomas. Acta Otolaryngol Suppl 1988;449: Eldridge R, Parry D. Vestibular schwannoma (acoustic neuroma). Consensus development conference. Neurosurgery 1992;30: Ogunrinde OK, Lunsford LD, Flickinger JC, et al. Cranial nerve preservation after stereotactic radiosurgery for small acoustic tumors. Arch Neurol 1995;52: Forster DM, Kemeny AA, Pathak A, et al. Radiosurgery: A minimally interventional alternative to microsurgery in the management of acoustic neuroma. Br J Neurosurg 1996;10: Baldwin DL, King TT, Morrison AW. Hearing conservation in acoustic neuroma surgery via the posterior fossa. J Laryngol Otol 1990;104: Nadol JB Jr, Chiong CM, Ojemann RG, et al. Preservation of hearing and facial nerve function in resection of acoustic neuroma. Laryngoscope 1992;102: Varlotto JM, Shrieve DC, Alexander E III, et al. Fractionated stereotactic radiotherapy for the treatment of acoustic neuromas: Preliminary results. Int J Radiat Oncol Biol Phys 1996; 36: Meijer OW, Vandertop WP, Baayen JC, et al. Single-fraction vs. fractionated linac-based stereotactic radiosurgery for vestibular schwannoma: A single-institution study. Int J Radiat Oncol Biol Phys 2003;56: Maire JP, Floquet A, Darrouzet V, et al. Fractionated radiation therapy in the treatment of stage III and IV cerebello-pontine angle neurinomas: Preliminary results in 20 cases. Int J Radiat Oncol Biol Phys 1992;23: Lederman G, Arbit E, Lowry J. Management of acoustic neuroma. N Engl J Med 1999;340: Glass J, Silverman CL, Axelrod R, et al. Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol 1997;20: Combs SE, Volk S, Schulz-Ertner D, et al. Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): Long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys 2005;63: Ito K, Kurita H, Sugasawa K, et al. Neuro-otological findings after radiosurgery for acoustic neurinomas. Arch Otolaryngol Head Neck Surg 1996;122: Flickinger JC, Kondziolka D, Maitz AH, et al. Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int J Radiat Oncol Biol Phys 2003;56: Ito K, Shin M, Matsuzaki M, et al. Risk factors for neurological complications after acoustic neurinoma radiosurgery: Refinement from further experiences. Int J Radiat Oncol Biol Phys 2000;48: Shelton C, Hitselberger WE, House WF, et al. Hearing pres-
7 SRS for acoustic neuroma S. E. COMBS et al ervation after acoustic tumor removal: Long-term results. Laryngoscope 1990;100: Pollock BE, Lunsford LD, Kondziolka D, et al. Outcome analysis of acoustic neuroma management: A comparison of microsurgery and stereotactic radiosurgery. Neurosurgery 1995; 36: Ogunrinde OK, Lunsford DL, Kondziolka DS, et al. Cranial nerve preservation after stereotactic radiosurgery of intracanalicular acoustic tumors. Stereotact Funct Neurosurg 1995; 64(Suppl. 1): Flickinger JC, Kondziolka D, Lunsford L. Fractionation of radiation treatment in acoustics. Rationale and evidence in comparison to radiosurgery. Neurochirurgie 2004;50: Kondziolka D, Lunsford LD, Flickinger JC. Intraparenchymal brain stem radiosurgery. Neurosurg Clin N Am 1993;4: Shirato H, Sakamoto T, Sawamura Y, et al. Comparison between observation policy and fractionated stereotactic radiotherapy (SRT) as an initial management for vestibular schwannoma. Int J Radiat Oncol Biol Phys 1999;44:
LONG-TERM FOLLOW-UP OF ACOUSTIC SCHWANNOMA RADIOSURGERY WITH MARGINAL TUMOR DOSES OF 12 TO 13 Gy
doi:10.1016/j.ijrobp.2007.01.001 Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 3, pp. 845 851, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front
More informationLong-term follow-up reveals low toxicity of radiosurgery for vestibular schwannoma q
Radiotherapy and Oncology 82 (2007) 83 89 www.thegreenjournal.com Vestibular schwannoma Long-term follow-up reveals low toxicity of radiosurgery for vestibular schwannoma q Isabelle Rutten a, *, Brigitta
More informationResults of acoustic neuroma radiosurgery: an analysis of 5 years experience using current methods
See the Letter to the Editor and the Response in this issue in Neurosurgical Forum, pp 141 142. J Neurosurg 94:1 6, 2001 Results of acoustic neuroma radiosurgery: an analysis of 5 years experience using
More informationThe New England Journal of Medicine LONG-TERM OUTCOMES AFTER RADIOSURGERY FOR ACOUSTIC NEUROMAS
LONG-TERM OUTCOMES AFTER RADIOSURGERY FOR ACOUSTIC NEUROMAS DOUGLAS KONDZIOLKA, M.D., L. DADE LUNSFORD, M.D., MARK R. MCLAUGHLIN, M.D., AND JOHN C. FLICKINGER, M.D. ABSTRACT Background Stereotactic radiosurgery
More informationCyberknife Radiotherapy for Vestibular Schwannoma
Cyberknife Radiotherapy for Vestibular Schwannoma GordonT. Sakamoto, MD a, *, Nikolas Blevins, MD b, Iris C. Gibbs, MD c KEYWORDS Stereotactic radiosurgery Vestibular schwannomas Cyberknife Fractionation
More informationS tereotactic radiosurgery, whether delivered by a gamma
1536 PAPER Gamma knife stereotactic radiosurgery for unilateral acoustic neuromas J G Rowe, M W R Radatz, L Walton, A Hampshire, S Seaman, A A Kemeny... See end of article for authors affiliations... Correspondence
More informationStereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2
Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2 Brian R. Subach, M.D., Douglas Kondziolka, M.D., M. Sc., F.R.C.S.(C), L. Dade Lunsford, M.D., F.A.C.S.,
More informationOtolaryngologist s Perspective of Stereotactic Radiosurgery
Otolaryngologist s Perspective of Stereotactic Radiosurgery Douglas E. Mattox, M.D. 25 th Alexandria International Combined ORL Conference April 18-20, 2007 Acoustic Neuroma Benign tumor of the schwann
More informationFRACTIONATED STEREOTACTIC RADIOTHERAPY FOR ACOUSTIC NEUROMAS
PII S0360-3016(02)02763-3 Int. J. Radiation Oncology Biol. Phys., Vol. 54, No. 2, pp. 500 504, 2002 Copyright 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/02/$ see front
More informationVestibular schwannoma (VS), also known as acoustic neuroma
ORIGINAL RESEARCH O.W.M. Meijer E.J. Weijmans D.L. Knol B.J. Slotman F. Barkhof W.P. Vandertop J.A. Castelijns Tumor-Volume Changes after Radiosurgery for Vestibular Schwannoma: Implications for Follow-
More informationAc o u s t i c neuromas, also known as vestibular. Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma
J Neurosurg 111:863 873, 2009 Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma Clinical article Hi d e y u k i Ka n o, M.D., Ph.D., 1,3 Do u g l a s Ko n d z i o
More informationAcoustic Neuroma. Presenting Signs and Symptoms of an Acoustic Neuroma:
Acoustic Neuroma An acoustic neuroma is a benign tumor which arises from the nerves behind the inner ear and which may affect hearing and balance. The incidence of symptomatic acoustic neuroma is estimated
More informationORIGINAL ARTICLE. Hearing Loss and Changes in Transient Evoked Otoacoustic Emissions After Gamma Knife Radiosurgery for Acoustic Neurinomas
ORIGINAL ARTICLE Hearing Loss and Changes in Transient Evoked Otoacoustic Emissions After Gamma Knife Radiosurgery for Acoustic Neurinomas Francesco Ottaviani, MD; Cesare Bartolomeo Neglia, MD; Laura Ventrella,
More informationRadiosurgical Treatment of Vestibular Schwannomas in Patients With Neurofibromatosis Type 2
Radiosurgical Treatment of Vestibular Schwannomas in Patients With Neurofibromatosis Type 2 Tumor Control and Hearing Preservation Ji Hoon Phi, MD 1, Dong Gyu Kim, MD, PhD 1, Hyun-Tai Chung, PhD 1, Joongyub
More informationStereotactic Radiosurgery/Fractionated Stereotactic Radiotherapy for Acoustic Neuroma (Vestibular Schwannomas)
Strategic Commissioning Group West Midlands Commissioning Policy (WM/38) Stereotactic Radiosurgery/Fractionated Stereotactic Radiotherapy for Acoustic Neuroma (Vestibular Schwannomas) Version 1 July 2010
More informationLINAC Radiosurgery and Radiotherapy Treatment of Acoustic Neuromas
Otolaryngol Clin N Am 40 (2007) 541 570 LINAC Radiosurgery and Radiotherapy Treatment of Acoustic Neuromas Ilya Likhterov, BA a, Robert M. Allbright, MD b, Samuel H. Selesnick, MD c,d,e, * a Weill Cornell
More informationSerial Follow-up MR Imaging after Gamma Knife Radiosurgery for Vestibular Schwannoma
AJNR Am J Neuroradiol 21:1540 1546, September 2000 Serial Follow-up MR Imaging after Gamma Knife Radiosurgery for Vestibular Schwannoma Hiroyuki Nakamura, Hidefumi Jokura, Kou Takahashi, Nagatoshi Boku,
More informationLinear accelerator radiosurgery for vestibular schwannoma
See the Letter to the Editor and the Response in this issue in Neurosurgical Forum, pp 142 144. J Neurosurg 94:7 13, 2001 Linear accelerator radiosurgery for vestibular schwannoma ROBERTO SPIEGELMANN,
More informationAcoustic neuromas (vestibular schwannomas) are generally
CHAPTER 6 Navigating Change and the Acoustic Neuroma Story: Methods, Outcomes, and Myths L. Dade Lunsford, M.D., F.A.C.S., Ajay Niranjan, M.B.B.S., M.Ch., John C. Flickinger, M.D., and Douglas Kondziolka,
More informationbrain talk brain talk IRSA Inside: Definition 2 Radiosurgery: First Choice for Many 3 Management Algorithm 7 SRS and FSR 8 Patient Story 9 Scanning 10
brain talk brain talk An Educational Publication Volume 9, Number 2 ISSN 1086-427X Acoustic Neuroma & Patient Choice Inside: Definition 2 : First Choice for Many 3 Management Algorithm 7 SRS and FSR 8
More informationRecently, GKS has been regarded as a major therapeutic. Nervus intermedius dysfunction following Gamma Knife surgery for vestibular schwannoma
J Neurosurg 118:566 570, 2013 AANS, 2013 Nervus intermedius dysfunction following Gamma Knife surgery for vestibular schwannoma Clinical article Seong-Hyun Park, M.D., 1 Kyu-Yup Lee, M.D., 2 and Sung-Kyoo
More informationAfter an evolution of more than 3 decades, stereotactic
Neuro-Oncology Advance Access published May 3, 2012 Neuro-Oncology doi:10.1093/neuonc/nos085 NEURO-ONCOLOGY Therapeutic profile of single-fraction radiosurgery of vestibular schwannoma: unrelated malignancy
More informationComparison of Growth Patterns of Acoustic Neuromas With and Without Radiosurgery
Otology & Neurotology 27:705 Y 712 Ó 2006, Otology & Neurotology, Inc. Comparison of Growth Patterns of Acoustic Neuromas With and Without Radiosurgery *Alex Battaglia, Bill Mastrodimos, and *Roberto Cueva
More informationPII S (01) CLINICAL INVESTIGATION
PII S0360-3016(01)01559-0 Int. J. Radiation Oncology Biol. Phys., Vol. 50, No. 5, pp. 1265 1278, 2001 Copyright 2001 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/01/$ see front
More informationDosimetry, see MAGIC; Polymer gel dosimetry. Fiducial tracking, see CyberKnife radiosurgery
Subject Index Acoustic neuroma, neurofibromatosis type 2 complications 103, 105 hearing outcomes 103, 105 outcome measures 101 patient selection 105 study design 101 tumor control 101 105 treatment options
More informationMANAGEMENT OF ACOUSTIC NEUROMA. Mr Nigel Mendoza Consultant Neurosurgeon West London Neurosciences Centre Charing Cross Hospital
MANAGEMENT OF ACOUSTIC NEUROMA Mr Nigel Mendoza Consultant Neurosurgeon West London Neurosciences Centre Charing Cross Hospital Acoustic Neuroma Vestibular Schwannoma Benign tumour that arises from the
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2015
More informationFOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR EPENDYMOMA
1 EVIDENCE SUMMARY REPORT FOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR EPENDYMOMA QUESTIONS TO BE ADDRESSED: 1. What is the evidence for the clinical effectiveness
More informationInjury to the facial nerve is a common complication. Efficacy of facial nerve sparing approach in patients with vestibular schwannomas
See the corresponding editorial in this issue, pp 915 916. J Neurosurg 115:917 923, 2011 Efficacy of facial nerve sparing approach in patients with vestibular schwannomas Clinical article Raqeeb Haque,
More informationVestibular schwannomas (acoustic neuromas) are. The newly diagnosed vestibular schwannoma: radiosurgery, resection, or observation?
Neurosurg Focus 33 (3):E8, 2012 The newly diagnosed vestibular schwannoma: radiosurgery, resection, or observation? Douglas Kondziolka, M.D., F.R.C.S.C., 1,2 Seyed H. Mousavi, M.D., 1,2 Hideyuki Kano,
More informationAlthough histologically benign, tumors LONG-TERM RESULTS AFTER RADIOSURGERY FOR BENIGN INTRACRANIAL TUMORS CLINICAL STUDIES
CLINICAL STUDIES LONG-TERM RESULTS AFTER RADIOSURGERY FOR BENIGN INTRACRANIAL TUMORS Douglas Kondziolka, M.D. Narendra Nathoo, M.D. John C. Flickinger, M.D. Ajay Niranjan, M.Ch. Ann H. Maitz, M.S. L. Dade
More informationFractionated Stereotactic Radiotherapy. Rationale, indications, & treatment techniques
Fractionated Stereotactic Radiotherapy Rationale, indications, & treatment techniques Radiobiological principles The BED (Gy) = D(1 + d/α/β) Assume BED 1 = BED 2 for tissue of an unknown α/β: Optic
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2013 Section:
More informationHemorrhagic vestibular schwannoma: an unusual clinical entity Case report
Neurosurg Focus 5 (3):Article 9, 1998 Hemorrhagic vestibular schwannoma: an unusual clinical entity Case report Dean Chou, M.D., Prakash Sampath, M.D., and Henry Brem, M.D. Departments of Neurological
More informationRevision Surgery for Vestibular Schwannomas
528 Original Article Kevin A. Peng 1 Brian S. Chen 3 Mark B. Lorenz 2 Gregory P. Lekovic 1 Marc S. Schwartz 1 William H. Slattery 1 Eric P. Wilkinson 1 1 House Clinic, Los Angeles, California, United States
More informationAcoustic neuromas, also known as vestibular
Neuro-Oncology 13(11):1252 1259, 2011. doi:10.1093/neuonc/nor118 Advance Access publication August 19, 2011 NEURO-ONCOLOGY Morbidity and mortality following acoustic neuroma excision in the United States:
More informationStereotactic radiosurgery (SRS) is the least invasive
» This article has been updated from its originally published version to correct Table 1 and terminology in the text. See the corresponding erratum notice, DOI: 10.3171/2017.3.JNS151624a. «CLINICAL ARTICLE
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017
More informationGamma knife radiosurgery for Koos grade 4 vestibular schwannomas
Gamma knife radiosurgery for Koos grade 4 vestibular schwannomas David Mathieu MD FRCSC, Christian Iorio-Morin MD PhD, Fahd Al Subaie MD MSc FRCSC Division of neurosurgery, Université de Sherbrooke, Centre
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015
More informationSPECIAL PAPER IN CELEBRATION OF PROF. YANG'S 50 YEARS CAREER IN MEDICINE
JOURNAL OF OTOLOGY SPECIAL PAPER IN CELEBRATION OF PROF. YANG'S 50 YEARS CAREER IN MEDICINE ADVANCES IN SURGICAL TREATMENT OF ACOUSTIC NEUROMA HAN Dongyi,CAI Chaochan Acoustic Neuroma (AN) arises from
More informationCerebellopontine angle (CPA) meningiomas are a. Stereotactic radiosurgery for cerebellopontine angle meningiomas. Clinical article
J Neurosurg 120:708 715, 2014 AANS, 2014 Stereotactic radiosurgery for cerebellopontine angle meningiomas Clinical article Seong-Hyun Park, M.D., Ph.D., 1,3,4 Hideyuki Kano, M.D., Ph.D., 1,3 Ajay Niranjan,
More informationStereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) Practice Guideline
Jour. of Radiosurgery and SBRT, Vol. 5, pp. 5-24 Reprints available directly from the publisher Photocopying permitted by license only 2017 Old City Publishing, Inc. Published by license under the OCP
More informationResults of Surgery of Cerebellopontine angle Tumors
Original Article Iranian Journal of Otorhinolaryngology, Vol. 27(1), Serial No.78, Jan 2015 Abstract Results of Surgery of Cerebellopontine angle Tumors Faramarz Memari 1, * Fatemeh Hassannia 1, Seyed
More informationNON MALIGNANT BRAIN TUMOURS Facilitator. Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol
NON MALIGNANT BRAIN TUMOURS Facilitator Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol Neurosurgery What will be covered? Meningioma Vestibular schwannoma (acoustic neuroma)
More informationStereotactic radiosurgery has been used STAGED STEREOTACTIC IRRADIATION CLINICAL STUDIES FOR ACOUSTIC NEUROMA
CLINICAL STUDIES STAGED STEREOTACTIC IRRADIATION FOR ACOUSTIC NEUROMA Steven D. Chang, M.D. Department of Neurosurgery, of Medicine, Stanford, California Iris C. Gibbs, M.D. Department of Radiation Oncology,
More informationSelected radiosurgery cases from the Rotating Gamma Institute Debrecen, Hungary
Selected radiosurgery cases from the Rotating Gamma Institute Debrecen, Hungary László Bognár M.D., Ph.D., József G. Dobai M.D., Gábor Csiky and Imre Fedorcsák M.D., Ph.D. Department of Neurosurgery, Medical
More informationThe Effect of Sub-Pixel MRI shifts on Radiosurgical Dosimetry for Vestibular Schwannomas. Departments of Neurosurgery 1 and Radiation Oncology 2,
The Effect of Sub-Pixel MRI shifts on Radiosurgical Dosimetry for Vestibular Schwannomas. Jonathan A. Borden, M.D. 1, Jen-San Tsai, Ph.D. 2 and Anita Mahajan, M.D. 2 Departments of Neurosurgery 1 and Radiation
More informationAcoustic Neuroma (vestibular schwannoma) basic level
Acoustic Neuroma (vestibular schwannoma) basic level Overview An acoustic neuroma is a tumor that grows from the nerves responsible for balance and hearing. More accurately called vestibular schwannoma,
More informationBackground Principles and Technical Development
Contents Part I Background Principles and Technical Development 1 Introduction and the Nature of Radiosurgery... 3 Definitions of Radiosurgery... 5 Consequences of Changing Definitions of Radiosurgery...
More informationExtracranial doses in stereotactic and conventional radiotherapy for pituitary adenomas
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 7, NUMBER 2, SPRING 2006 Extracranial doses in stereotactic and conventional radiotherapy for pituitary adenomas Thomas Samuel Ram, a Paul B. Ravindran,
More informationManagement of Cerebrospinal Fluid Leaks After Vestibular Schwannoma Surgery
Otology & Neurotology 32:1525Y1529 Ó 2011, Otology & Neurotology, Inc. Management of Cerebrospinal Fluid Leaks After Vestibular Schwannoma Surgery *Brannon D. Mangus, *Alejandro Rivas, Mi Jin Yoo, JoAnn
More informationAcoustic Neuroma (vestibular schwannoma)
1 2 Acoustic Neuroma (vestibular schwannoma) Overview An acoustic neuroma is a tumor that grows from the nerves responsible for balance and hearing. These tumors grow from the sheath covering the vestibulocochlear
More informationEvaluation of Variation in the Course of the Facial Nerve, Nerve Adhesion to Tumors, and Postoperative Facial Palsy in Acoustic Neuroma
Original Article 39 Evaluation of Variation in the Course of the Facial Nerve, Nerve Adhesion to Tumors, and Postoperative Facial Palsy in Acoustic Neuroma Tetsuro Sameshima 1 Akio Morita 1 Rokuya Tanikawa
More informationSponsored by: Congress of Neurological Surgeons (CNS) and the Section on Tumors
1 2 3 4 5 6 7 8 CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINE ON THE ROLE OF RADIOSURGERY AND RADIATION THERAPY IN THE MANAGEMENT OF PATIENTS WITH VESTIBULAR SCHWANNOMAS
More informationANALYSIS OF TREATMENT OUTCOMES WITH LINAC BASED STEREOTACTIC RADIOSURGERY IN INTRACRANIAL ARTERIOVENOUS MALFORMATIONS
ANALYSIS OF TREATMENT OUTCOMES WITH LINAC BASED STEREOTACTIC RADIOSURGERY IN INTRACRANIAL ARTERIOVENOUS MALFORMATIONS Dr. Maitri P Gandhi 1, Dr. Chandni P Shah 2 1 Junior resident, Gujarat Cancer & Research
More informationOriginal Date: April 2016 Page 1 of 7 FOR CMS (MEDICARE) MEMBERS ONLY
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIATION THERAPY: STEREO RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: Please refer to pages 5-6 LCD
More informationPostoperative Nerve Injury and Recurrence in Surgical Treatment of Head and Neck Schwannomas
Postoperative Nerve Injury and Recurrence in Surgical Treatment of Head and Neck Schwannomas SHU-HSIEN CHEN 1, PEI-YIEN TSAI 2, YEN-HUI 3 TSAI * AND CHIH-YING LIN 4 1 Institute of Health Industry Management
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 04/01/2014 Section:
More informationAcoustic Neurinomas. *Mohammad Faraji Rad 1
Iranian Journal of Otorhinolaryngology Vol. 23, No.1, Winter-2011 Review Article Acoustic Neurinomas *Mohammad Faraji Rad 1 Abstract Acoustic neuromas (AN) are schwann cell-derived tumors that commonly
More informationFractionated Proton Beam Therapy for Acoustic Neuromas: Tumor Control and Hearing Preservation
Fractionated Proton Beam Therapy for Acoustic Neuromas: Tumor Control and Hearing Preservation Carolyn J. Barnes, MD 1 ; David A. Bush, MD 1 ; Roger I. Grove, MPH 1 ; Lilia N. Loredo, MD 1 ; Jerry D. Slater,
More informationChapter 5 Section 3.1
Radiology Chapter 5 Section 3.1 Issue Date: March 27, 1991 Authority: 32 CFR 199.4(b)(2), (b)(2)(x), (c)(2)(viii), and (g)(15) 1.0 CPT 1 PROCEDURE CODES 37243, 61793, 61795, 77261-77421, 77427-77799, 0073T
More informationFunctional outcome after gamma knife surgery or microsurgery for vestibular schwannomas
J Neurosurg 97:1091 1100, 2002 Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas JEAN RÉGIS, M.D., WILLIAM PELLET, M.D., CHRISTINE DELSANTI, M.D., HENRY DUFOUR, M.D.,
More informationACOUSTIC NEUROMAS. Being invited to Florence, Italy to address an international medical meeting about our work for
ACOUSTIC NEUROMAS Being invited to Florence, Italy to address an international medical meeting about our work for head and neck tumors was a great honor. The symposium organized under the auspices of the
More informationORIGINAL ARTICLE GAMMA KNIFE STEREOTACTIC RADIOSURGERY FOR SALIVARY GLAND NEOPLASMS WITH BASE OF SKULL INVASION FOLLOWING NEUTRON RADIOTHERAPY
ORIGINAL ARTICLE GAMMA KNIFE STEREOTACTIC RADIOSURGERY FOR SALIVARY GLAND NEOPLASMS WITH BASE OF SKULL INVASION FOLLOWING NEUTRON RADIOTHERAPY James G. Douglas, MD, MS, 1,2 Robert Goodkin, MD, 1,2 George
More informationFOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR PILOCYTIC ASTROCYTOMA
1 EVIDENCE SUMMARY REPORT FOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR PILOCYTIC ASTROCYTOMA QUESTIONS TO BE ADDRESSED: SUMMARY 1. What is the evidence for the clinical
More informationStereotactic Radiosurgery. Extracranial Stereotactic Radiosurgery. Linear accelerators. Basic technique. Indications of SRS
Stereotactic Radiosurgery Extracranial Stereotactic Radiosurgery Annette Quinn, MSN, RN Program Manager, University of Pittsburgh Medical Center Using stereotactic techniques, give a lethal dose of ionizing
More informationParaganglioma of the Skull Base. Ross Zeitlin, MD Medical College of Wisconsin Milwaukee, WI
Paraganglioma of the Skull Base Ross Zeitlin, MD Medical College of Wisconsin Milwaukee, WI Case Presentation 63-year-old female presents with right-sided progressive conductive hearing loss for several
More informationDr. T. Venkat Kishan Asst. Prof Department of Radiodiagnosis
Dr. T. Venkat Kishan Asst. Prof Department of Radiodiagnosis Schwannomas (also called neurinomas or neurilemmomas) constitute the most common primary cranial nerve tumors. They are benign slow-growing
More informationLixana Vega Vega, MD Long Island College Hospital Department of Surgery
Lixana Vega Vega, MD Long Island College Hospital Department of Surgery 59 y/o male presented w/ a palpable left neck mass. PMH: DM, Hyperlipidemia, left acoustic neuroma 5x3mm and pituitary macroadenoma
More informationGamma Knife Radiosurgery
Gamma Knife Radiosurgery A Team Approach to Treating Patients George Bovis, MD Patrick Sweeney, MD Jagan Venkatesan, MS Matt White, MS Illinois Gamma Knife Center Elk Grove Village, IL Disclosures Shareholders
More informationGamma Knife radiosurgery for large vestibular schwannomas greater than 3 cm in diameter
CLINICAL ARTICLE J Neurosurg 128:1380 1387, 2018 Gamma Knife radiosurgery for large vestibular schwannomas greater than 3 cm in diameter Cheng-Wei Huang, MD, 1,4 Hsien-Tang Tu, BS, 1 Chun-Yi Chuang, MD,
More informationYear 2003 Paper two: Questions supplied by Tricia
question 43 A 42-year-old man presents with a two-year history of increasing right facial numbness. He has a history of intermittent unsteadiness, mild hearing loss and vertigo but has otherwise been well.
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationForward treatment planning techniques to reduce the normalization effect in Gamma Knife radiosurgery
Received: 7 November 2016 Revised: 9 August 2017 Accepted: 21 August 2017 DOI: 10.1002/acm2.12193 RADIATION ONCOLOGY PHYSICS Forward treatment planning techniques to reduce the normalization effect in
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationGamma Knife radiosurgery with CT image-based dose calculation
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 16, NUMBER 6, 2015 Gamma Knife radiosurgery with CT image-based dose calculation Andy (Yuanguang) Xu, 1a Jagdish Bhatnagar, 1 Greg Bednarz, 1 Ajay Niranjan,
More informationUse of the Leksell gamma knife C with automatic positioning system for the treatment of meningioma and vestibular schwannoma
Neurosurg Focus 14 (5):Article 8, 2003, Click here to return to Table of Contents Use of the Leksell gamma knife C with automatic positioning system for the treatment of meningioma and vestibular schwannoma
More informationSUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT
SUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT Cheng-Ta Hsieh, 1 Cheng-Fu Chang, 1 Ming-Ying Liu, 1 Li-Ping Chang, 2 Dueng-Yuan Hueng, 3 Steven D. Chang, 4 and Da-Tong Ju 1
More informationIMAGE-GUIDED RADIOSURGERY USING THE GAMMA KNIFE
IMAGE-GUIDED RADIOSURGERY USING THE GAMMA KNIFE L. D. LUNSFORD INTRODUCTION Image guided brain surgery became a reality in the mid-1970s after the introduction of the first methods to obtain axial imaging
More informationGamma Knife surgery for trigeminal schwannoma
J Neurosurg 106:839 845, 2007 Gamma Knife surgery for trigeminal schwannoma JASON SHEEHAN, M.D., PH.D., CHUN PO YEN, M.D., YASSER ARKHA, M.D., DAVID SCHLESINGER, PH.D., AND LADISLAU STEINER, M.D., PH.D.
More informationAcoustic Neuroma (vestibular schwannoma)
Acoustic Neuroma (vestibular schwannoma) Overview An acoustic neuroma is a tumor that grows from the nerves responsible for balance and hearing. These tumors grow from the sheath covering the vestibulocochlear
More informationGamma Knife Radiosurgery A tool for treating intracranial conditions. CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop
Gamma Knife Radiosurgery A tool for treating intracranial conditions CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop ANGELA McBEAN Gamma Knife CNC State-wide Care Coordinator Gamma Knife
More informationFOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR HAEMANGIOBLASTOMA
1 EVIDENCE SUMMARY REPORT FOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR HAEMANGIOBLASTOMA QUESTIONS TO BE ADDRESSED: 1. What is the evidence for the clinical effectiveness
More informationTrigeminal neuralgia and neuropathy in large sporadic vestibular schwannomas
CLINICAL ARTICLE J Neurosurg 127:992 999, 2017 Trigeminal neuralgia and neuropathy in large sporadic vestibular schwannomas Brian A. Neff, MD, 1 Matthew L. Carlson, MD, 1 Megan M. O Byrne, MA, 3 Jamie
More informationLeksell Gamma Knife Icon. Treatment information
Leksell Gamma Knife Icon Treatment information You may be feeling frightened or overwhelmed by your recent diagnosis. It can be confusing trying to process a diagnosis, understand a new and challenging
More informationVe s t i b u l a r schwannomas are benign tumors that. Sporadic unilateral vestibular schwannoma in the pediatric population.
J Neurosurg Pediatrics 4:000 000, 4:125 129, 2009 Sporadic unilateral vestibular schwannoma in the pediatric population Clinical article Br i a n P. Wa l c o t t, M.D., 1,2 Ga n e s h Si va r a ja n, B.S.,
More informationWith advances in microsurgical techniques and the. Staged resection of large vestibular schwannomas. Clinical article
J Neurosurg 116:1126 1133, 2012 Staged resection of large vestibular schwannomas Clinical article Ahmed M. Raslan, M.D., 1 James K. Liu, M.D., 3 Sean O. McMenomey, M.D., 1,2 and Johnny B. Delashaw Jr.,
More informationAbstractID: 8073 Title: Quality Assurance, Planning and Clinical Results for Gamma Knife Radiosurgery S. Goetsch, Ph.D. Page 1 Seattle, WA May 2008
Knife Radiosurgery S. Goetsch, Ph.D. Page 1 Quality Assurance, Planning and Clinical Results for Gamma Knife Radiosurgery Steven J. Goetsch, Ph.D., FAAPM ACMP 25 th Annual Meeting Seattle, WA May 2008
More informationOverview of MLC-based Linac Radiosurgery
SRT I: Comparison of SRT Techniques 1 Overview of MLC-based Linac Radiosurgery Grace Gwe-Ya Kim, Ph.D. DABR 2 MLC based Linac SRS Better conformity for irregular target Improved dose homogeneity inside
More information2. Department of Neurologic Surgery, Mayo Clinic, School of Medicine, Rochester, Minnesota,
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINE ON HEARING PRESERVATION OUTCOMES IN PATIENTS WITH
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/36461 holds various files of this Leiden University dissertation Author: Wiggenraad, Ruud Title: Stereotactic radiotherapy of intracranial tumors : optimizing
More informationIS SMALLER BETTER? COMPARISON OF 3-MM AND 5-MM LEAF SIZE FOR STEREOTACTIC RADIOSURGERY: A DOSIMETRIC STUDY
Int. J. Radiation Oncology Biol. Phys., Vol. 66, No. 4, Supplement, pp. S76 S81, 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/06/$ see front matter doi:10.1016/j.ijrobp.2006.04.061
More informationRadiotherapy in the management of optic pathway gliomas
Turkish Journal of Cancer Vol.30/ No.1/2000 Radiotherapy in the management of optic pathway gliomas FARUK ZORLU, FERAH YILDIZ, MURAT GÜRKAYNAK, FADIL AKYOL, İ. LALE ATAHAN Department of Radiation Oncology,
More informationOverview of radiosurgery for benign brain tumors
Overview of radiosurgery for benign brain tumors Anuj V. Peddada, M.D. Department of Radiation Oncology Penrose Cancer Center Colorado Springs, CO Objectives Provide overview of benign brain tumors meningiomas
More informationThe Classification of Posterior Petrous Meningiomas and Its Clinical Significance
The Journal of International Medical Research 2009; 37: 949 957 [first published online as 37(3) 13] The Classification of Posterior Petrous Meningiomas and Its Clinical Significance FJ QU 1 *, XD ZHOU
More informationEvidence Based Medicine for Gamma Knife Radiosurgery. Metastatic Disease GAMMA KNIFE SURGERY
GAMMA KNIFE SURGERY Metastatic Disease Evidence Based Medicine for Gamma Knife Radiosurgery Photos courtesy of Jean Régis, Timone University Hospital, Marseille, France Brain Metastases The first report
More informationTania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015
Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015 Most common brain tumor, affecting 8.5-15% of cancer patients. Treatment options: Whole brain radiation
More informationSpecialised Services Policy: CP22. Stereotactic Radiosurgery
Specialised Services Policy: CP22 Document Author: Assistant Director of Planning Executive Lead: Director of Planning ad Performance Approved by: Management Group Issue Date: 01 July 2015 Review Date:
More informationCapt. Nazim ATA Aerospace Medicine Specialist Turkish Air Force AAMIMO 2013
F-15 Pilot with ACOUSTIC NEUROMA Capt. Nazim ATA Aerospace Medicine Specialist Turkish Air Force AAMIMO 2013 Disclosure Information 84 th Annual AsMA Scientific Meeting Nazim ATA I have no financial relationships
More information